Wyden is a global leader in institutional digital asset trading technology. Its platform covers the entire trade lifecycle—from pre‑trade risk checks and order generation to automated settlement—while integrating custody, core banking, and portfolio management systems. Built by a team of trading system veterans and crypto asset experts, the solution delivers full trade‑lifecycle automation and seamless integration with traditional financial infrastructure, enabling institutions to bridge digital and conventional assets.
DgPays is a financial technology company that delivers end-to-end payment systems for banks, e-money institutions, telecom operators, and transportation operators. Its platform supports online and mobile banking, customer relationship management, and payments infrastructure, enabling secure and convenient online and mobile transactions. The company offers features such as mobile wallets, prepaid cards, bill payments, and loyalty programs, as well as a payment gateway and related fintech hub to manage payments and access a range of financial services. In addition, DgPays provides compliance and security services, including AML, fraud management, and authentication, to support safe operations. Through its integrated solutions, DgPays aims to streamline payment processing, expand wallet and card-based payment options, and enhance payment experiences for institutional clients and their end users.
Obat is a developer of invoicing and payment software tailored for small and medium enterprises in the construction industry. The company provides a platform that includes features for estimation, project management, site monitoring, and invoicing specifically for building craftsmen. By continually adapting its software based on feedback from customers and partners, Obat aims to help contractors and independent contractors enhance their operational efficiency and maximize their value proposition.
Levenue is a European platform facilitating revenue-based financing. It connects institutional investors with founders/CFOs of recurring revenue companies, providing growth capital without shareholder dilution or high consumer discounts.
MoneyTrack
Series A in 2023
MoneyTrack is a global blockchain platform facilitating directed money exchanges between financers, beneficiaries, and partners. It enables clients to create custom programs with configurable characteristics, pricing, and commission structures, reducing operational costs and enhancing market access.
Obat is a developer of invoicing and payment software tailored for small and medium enterprises in the construction industry. The company provides a platform that includes features for estimation, project management, site monitoring, and invoicing specifically for building craftsmen. By continually adapting its software based on feedback from customers and partners, Obat aims to help contractors and independent contractors enhance their operational efficiency and maximize their value proposition.
Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.
Bridge
Venture Round in 2022
Bridge is a banking data and payment system. They offer banking aggregation, payment initiation, open data, electronic invoices, debt collection, e-commerce sites and digital and physical commerce, factoring, kitty service, wallets, single and multiple payments, finance and insurance, credit, risk, and fraud experts.
Cachet OÜ, established in 2018 and headquartered in Tallinn, Estonia, operates an innovative online insurance brokerage platform focused on the mobility sector, particularly for ride-hailing drivers. The company offers a variety of insurance products, including traffic and casco insurance, as well as fleet insurance. Cachet serves as a data intermediary between gig economy platforms and insurance providers by aggregating and enriching data on service provision across multiple platforms. This data-driven approach enables insurance companies to deliver personalized coverage options tailored to individual service providers based on their actual working hours, thereby enhancing pricing, predictability, and risk management within the gig and sharing economy.
RollingFunds
Venture Round in 2022
Founded in 2018 and headquartered in Paris, France, RollingFunds specializes in providing short-term financing solutions to small and medium-sized enterprises. Its proprietary platform employs machine learning-based algorithms for instant credit scoring, automating loan granting and management processes.
Cake App
Seed Round in 2022
Cake App mission is to become the leading software technology provider that analyzes financial data to help people better understand, control and improve their finances, supported by a business model that shares our revenue with users.
IPaidThat
Venture Round in 2021
IPaidThat automates invoice management by importing invoices and matching them with bank transactions. Its platform offers tools for efficient bank reconciliation, automated payment processing, and accurate data extraction using OCR.
Monisnap SAS is a French fintech company based in Paris, founded in 2017. It operates a digital instant money transfer platform and mobile application designed to facilitate the sending of money abroad. The platform allows users to transfer funds quickly and efficiently to family, friends, and business partners from Europe to various destinations worldwide. Monisnap aims to enhance the remittance experience by offering a seamless and user-friendly service.
Zaion specializes in AI-driven conversational platforms designed to optimize customer relations. Its platform automates conversations using intelligence, offering voice customer relationship processing through remote advisors for enhanced customer satisfaction and reduced operational costs.
Acasi SAS is a company based in Paris, France, that specializes in developing accounting management software tailored for freelancers across various sectors, including architecture, law, consultancy, and coaching. Founded in 2017, Acasi's software streamlines financial management by automating tasks such as online quotations, invoicing, VAT management, and expense tracking. Additionally, it provides real-time cash monitoring and personalized financial coaching, helping users alleviate the administrative burdens associated with their accounting practices. Through its innovative solutions, Acasi aims to enhance the efficiency and effectiveness of financial management for freelancers.
MoneyTrack
Series A in 2021
MoneyTrack is a global blockchain platform facilitating directed money exchanges between financers, beneficiaries, and partners. It enables clients to create custom programs with configurable characteristics, pricing, and commission structures, reducing operational costs and enhancing market access.
Smile&Pay
Series B in 2021
Smile & Pay is a company that specializes in electronic payment solutions, providing small and medium-sized merchants with innovative tools to accept payments via smartphones. Its product lineup includes PocketSmile, a compact mobile terminal that accommodates all credit cards, and MaxiSmile, which features both a printer and mobile GPRS capabilities. In addition to facilitating card payments, Smile & Pay offers software that allows users to track and manage transactions and accounts online, enabling efficient payment processing in various settings without the need for traditional payment terminals. By focusing on user-friendly technology, Smile & Pay enhances the payment experience for both merchants and customers.
Particeep
Venture Round in 2021
Particeep is a fintech company that specializes in providing banks, insurers, asset managers, and their distributors with efficient, no-code solutions for the online distribution of financial products and services. The company offers a platform that allows these institutions to establish digital subscription channels quickly—typically within a month—without the need for any IT development. Particeep's services include a REST API composed of micro-services tailored for banking, insurance, and investment sectors, facilitating seamless data sharing with various information systems and third-party applications. This innovative approach enables financial institutions to enhance their digital capabilities and streamline their product offerings effectively.
WeGroup is a Belgian InsurTech company that helps insurance providers connect with digital customers by leveraging data analytics and robotic automation. Its 24/7 virtual assistant, Louise, enables faster, more personal service and supports brokers in serving a growing digital client base. The company analyzes customer needs and predicts risk exposure to increase sales and improve portfolio quality while reducing operational overhead. Its solutions are used by insurance companies, intermediaries, and banks across Europe.
Monisnap
Seed Round in 2019
Monisnap SAS is a French fintech company based in Paris, founded in 2017. It operates a digital instant money transfer platform and mobile application designed to facilitate the sending of money abroad. The platform allows users to transfer funds quickly and efficiently to family, friends, and business partners from Europe to various destinations worldwide. Monisnap aims to enhance the remittance experience by offering a seamless and user-friendly service.
RollingFunds
Series A in 2019
Founded in 2018 and headquartered in Paris, France, RollingFunds specializes in providing short-term financing solutions to small and medium-sized enterprises. Its proprietary platform employs machine learning-based algorithms for instant credit scoring, automating loan granting and management processes.
IPaidThat
Seed Round in 2019
IPaidThat automates invoice management by importing invoices and matching them with bank transactions. Its platform offers tools for efficient bank reconciliation, automated payment processing, and accurate data extraction using OCR.
Smile&Pay
Venture Round in 2018
Smile & Pay is a company that specializes in electronic payment solutions, providing small and medium-sized merchants with innovative tools to accept payments via smartphones. Its product lineup includes PocketSmile, a compact mobile terminal that accommodates all credit cards, and MaxiSmile, which features both a printer and mobile GPRS capabilities. In addition to facilitating card payments, Smile & Pay offers software that allows users to track and manage transactions and accounts online, enabling efficient payment processing in various settings without the need for traditional payment terminals. By focusing on user-friendly technology, Smile & Pay enhances the payment experience for both merchants and customers.
MoneyTrack
Funding Round in 2017
MoneyTrack is a global blockchain platform facilitating directed money exchanges between financers, beneficiaries, and partners. It enables clients to create custom programs with configurable characteristics, pricing, and commission structures, reducing operational costs and enhancing market access.
Geocorail
Venture Round in 2015
Géocorail développe et commercialise un produit innovant faisant travailler la mer à la protection du littoral : le Géocorail®. Ce procédé électrochimique breveté innovant consiste à créer une roche artificielle permettant de protéger les ouvrages marins et de lutter contre l’érosion du littoral.
Theraclion is a French company founded in 2004, specializing in high-tech medical equipment that utilizes high-intensity focused ultrasound (HIFU) for therapeutic purposes. It develops, manufactures, and markets innovative medical devices, notably the Echopulse®, designed for the non-invasive treatment of breast fibroadenomas and benign thyroid nodules. Additionally, the company offers the SONOVEIN®, which is aimed at treating varicose veins in the lower limbs. Theraclion’s echotherapy solutions integrate HIFU with ultrasound technology, enabling precise localization of target areas for effective treatment of benign tumors and varicose veins.
Myopowers Medical Technologies
Series C in 2015
Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area.
The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation.
ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.
Actility develops ThingPark, a machine-to-machine communication platform designed for large-scale deployments of critical applications. It offers carrier-grade IoT solutions, including low-power wide-area networks, middleware, and an IoT device marketplace. Actility is a founding member of the LoRa Alliance.
Altimmune is a biopharmaceutical company focused on developing immunotherapies, vaccines, and treatments for liver diseases. Its pipeline includes HepTcell for hepatitis B, NasoShield and AdCOVID for anthrax and COVID-19 respectively, both delivered intranasally, and ALT-801 for non-alcoholic steatohepatitis.
SP3H
Venture Round in 2014
SP3H specializes in developing optical sensing technology for real-time fuel analysis. Its platform employs near-infrared spectroscopy and embedded algorithms to detect molecular fuel composition, enabling automotive and energy sectors to optimize engine performance, reduce emissions, and monitor fuel quality using compact, on-board sensors.
CoolGames
Series A in 2013
CoolGames is a developer of cloud-based interactive and casual games, focusing on delivering high-quality gaming experiences to players worldwide. Since its establishment in 2009, the company has utilized 100% HTML5 technology to publish a diverse portfolio of games, including well-known intellectual properties such as Angry Birds, Tetris, Snake, and Battleship. By offering a click-and-play platform, CoolGames allows users to access and enjoy its games on various devices, including smartphones, personal computers, and tablets, without the need for downloads. This approach ensures that players can engage with their favorite games anytime and anywhere, reflecting the company's commitment to providing accessible and enjoyable gaming experiences.
MoMac is a global technology company specializing in customer engagement solutions for leading Communication Service Providers (CSPs). It operates the mvolve platform, which integrates internal data systems, service offerings, content, and on-device user interfaces to enhance CSP-customer interactions. This integration enables CSPs to reduce costs, increase revenue, and accelerate solution deployment. MoMac serves prominent CSP clients such as Orange Group, Vodafone, Telefónica, Three, KPN, and T-Mobile across 27 countries, with offices in the US, UK, Netherlands, and France.
Carbios
Funding Round in 2012
Carbios is a company focused on developing innovative enzymatic bioprocesses for recycling plastic and textile polymers. It specializes in creating biodegradable plastics through a method that enables the recycling of plastic waste, particularly polyethylene terephthalate (PET), which is commonly found in bottles and containers. By utilizing enzymes to decompose and recycle PET, Carbios aims to promote a circular economy and mitigate the environmental issues associated with plastic pollution. The company is committed to advancing sustainable technologies, offering a new generation of fully biodegradable plastics with controlled lifespans and infinite recycling capabilities. Through its biorecycling and bioproduction techniques, Carbios seeks to contribute to a more sustainable future by addressing the challenges posed by plastic waste.
SP3H
Venture Round in 2012
SP3H specializes in developing optical sensing technology for real-time fuel analysis. Its platform employs near-infrared spectroscopy and embedded algorithms to detect molecular fuel composition, enabling automotive and energy sectors to optimize engine performance, reduce emissions, and monitor fuel quality using compact, on-board sensors.
Pharnext
Venture Round in 2012
Pharnext SA is a clinical-stage biopharmaceutical company based in Issy-Les-Moulineaux, France, founded in 2007 by leading scientists in genomics. The company focuses on developing innovative therapies for both orphan and common neurodegenerative diseases, where treatment options are currently limited. Its notable products include SYNGILITY, which has successfully completed Phase III trials for Charcot-Marie-Tooth disease type 1A, and PXT864, which has shown promise in Phase II trials for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Pharnext employs its proprietary PLEOTHERAPY platform, which utilizes network pharmacology and extensive genomic data to identify synergistic combinations of existing approved drugs, termed PLEODRUGs. This approach aims to optimize drug efficacy and safety while securing intellectual property through granted patents. Additionally, Pharnext has collaborated with the University Hospital Institute Mediterranee Infection to explore repurposed drugs for potential COVID-19 applications.
CoolGames
Funding Round in 2012
CoolGames is a developer of cloud-based interactive and casual games, focusing on delivering high-quality gaming experiences to players worldwide. Since its establishment in 2009, the company has utilized 100% HTML5 technology to publish a diverse portfolio of games, including well-known intellectual properties such as Angry Birds, Tetris, Snake, and Battleship. By offering a click-and-play platform, CoolGames allows users to access and enjoy its games on various devices, including smartphones, personal computers, and tablets, without the need for downloads. This approach ensures that players can engage with their favorite games anytime and anywhere, reflecting the company's commitment to providing accessible and enjoyable gaming experiences.
Biokinesis
Funding Round in 2011
Biokinesis is a biotechnology company developing new treatments for cancer by targeting a specific kinesin found in several cancers.
Pharnext SA is a clinical-stage biopharmaceutical company based in Issy-Les-Moulineaux, France, founded in 2007 by leading scientists in genomics. The company focuses on developing innovative therapies for both orphan and common neurodegenerative diseases, where treatment options are currently limited. Its notable products include SYNGILITY, which has successfully completed Phase III trials for Charcot-Marie-Tooth disease type 1A, and PXT864, which has shown promise in Phase II trials for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Pharnext employs its proprietary PLEOTHERAPY platform, which utilizes network pharmacology and extensive genomic data to identify synergistic combinations of existing approved drugs, termed PLEODRUGs. This approach aims to optimize drug efficacy and safety while securing intellectual property through granted patents. Additionally, Pharnext has collaborated with the University Hospital Institute Mediterranee Infection to explore repurposed drugs for potential COVID-19 applications.
Myopowers Medical Technologies
Series B in 2011
Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area.
The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation.
ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.
Utel
Venture Round in 2011
Utel SAS, based in Paris, France, specializes in creating mobile applications for social networking and collaborative services. The company's flagship platform, Allokang, enables users to buy or sell skills, talents, and expertise across various fields, including legal, financial, academic support, IT, mental health, personal development, entertainment, and astrology. Additionally, Utel offers Backstage SMS, which provides tools for interactive engagement such as game initiation and voting, alongside a web interface that allows animators to manage listener messages and multimedia submissions. This functionality also enables monetization of community page traffic, allowing users to participate in paid activities. Established in 2000, Utel continues to innovate in the mobile application space.
Actility
Seed Round in 2010
Actility develops ThingPark, a machine-to-machine communication platform designed for large-scale deployments of critical applications. It offers carrier-grade IoT solutions, including low-power wide-area networks, middleware, and an IoT device marketplace. Actility is a founding member of the LoRa Alliance.
Pharnext SA is a clinical-stage biopharmaceutical company based in Issy-Les-Moulineaux, France, founded in 2007 by leading scientists in genomics. The company focuses on developing innovative therapies for both orphan and common neurodegenerative diseases, where treatment options are currently limited. Its notable products include SYNGILITY, which has successfully completed Phase III trials for Charcot-Marie-Tooth disease type 1A, and PXT864, which has shown promise in Phase II trials for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Pharnext employs its proprietary PLEOTHERAPY platform, which utilizes network pharmacology and extensive genomic data to identify synergistic combinations of existing approved drugs, termed PLEODRUGs. This approach aims to optimize drug efficacy and safety while securing intellectual property through granted patents. Additionally, Pharnext has collaborated with the University Hospital Institute Mediterranee Infection to explore repurposed drugs for potential COVID-19 applications.
Immune Targeting Systems
Series A in 2010
Immune Targeting Systems Limited is a biotechnology company focused on developing synthetic vaccines for mutating viruses. Based in London at the London BioScience Innovation Centre, the company was founded in late 2003. Its core technology involves targeting highly conserved parts of viruses to direct a T-cell immune response against infected cells. The company's fluoropeptide vaccine technology delivers these antigens into the body, promoting robust T-cell immunity without needing potentially toxic adjuvants typically used to boost vaccine responses. ITS is developing FP-01, a synthetic vaccine effective against various seasonal and pandemic influenza strains, as well as vaccines for life-threatening viral infections such as HIV/AIDS, hepatitis, and FIV (cat AIDS).
Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.
Eco-Carbone
Funding Round in 2008
Eco-Carbone provides consulting and project development services in the area of climate change mitigation.
Carmat
Funding Round in 2008
Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.
OSEAD Maroc Mining
Private Equity Round in 2007
OSEAD Maroc Mining operates as a metal and mining platform.
OSEAD is a holding company specialising in the prospecting, exploration and mining of mineral deposits. OSEAD’s main asset is Compagnie Minière de Touissit the second largest private mining operator in Morocco, which mines primarily lead and silver with some zinc.
PeopleCube
Venture Round in 2007
PeopleCube is a provider of intelligent on-demand workplace management solutions headquartered in Framingham, Massachusetts, with additional offices worldwide. The company offers a suite of software designed for scheduling and facility management, enabling organizations to optimize their workspace usage and reduce costs associated with real estate, meeting services, travel, and energy. Among its offerings are resource scheduling software, which facilitates the management of alternative workspaces, room bookings, video conferencing, and visitor and event management. With a customer base of approximately 7,500 organizations across various sectors, PeopleCube aims to enhance operational efficiency through its data-driven approach to workplace management.
Neovacs
Venture Round in 2007
Neovacs is a biotechnology company founded in 1993 as a spin-off from the Pierre & Marie Curie University in Paris by Professor Daniel Zagury, a prominent immunologist. The company specializes in the development of therapeutic vaccines known as "Kinoids," which are designed to treat a range of conditions including autoimmune diseases, allergies, and cancer. Neovacs holds an extensive patent portfolio and is recognized for its innovative approach to vaccine development, particularly in creating vaccines that target human cytokines and immunosuppressive viral proteins. Unlike traditional monoclonal antibody treatments that provide exogenous therapies, Neovacs' therapeutic vaccines promote a robust natural polyclonal antibody response in patients, positioning the company as a pioneer in the field of immunotherapy.
Immune Targeting Systems
Series A in 2007
Immune Targeting Systems Limited is a biotechnology company focused on developing synthetic vaccines for mutating viruses. Based in London at the London BioScience Innovation Centre, the company was founded in late 2003. Its core technology involves targeting highly conserved parts of viruses to direct a T-cell immune response against infected cells. The company's fluoropeptide vaccine technology delivers these antigens into the body, promoting robust T-cell immunity without needing potentially toxic adjuvants typically used to boost vaccine responses. ITS is developing FP-01, a synthetic vaccine effective against various seasonal and pandemic influenza strains, as well as vaccines for life-threatening viral infections such as HIV/AIDS, hepatitis, and FIV (cat AIDS).
Cytomics Pharmaceuticals
Series B in 2006
Cytomics Systems is a French private company that offers bio-pharmacology services. The company uses Yeast Micro-Lab technology, a protenomics tool, which enables to follow in-vitro deterioration of proteins. Cytomics Systems's research and development focuses on fungicidal infections, inflammatory illnesses, and cancers. Cytomics Systems, S.A was founded in 2000 and is based in Gif-sur-Yvette, France.
RF-IT Solutions
Series A in 2006
RF-iT Solutions GmbH specializes in radio frequency identification (RFID) software solutions and services, established in 2005 and headquartered in Graz, Austria, with additional locations in Germany, France, and the United Kingdom. The company develops and markets a range of products, including the You-R® OPEN platform, designed for system integrators and software manufacturers, and a variety of RFID infrastructure tools such as smart labels, readers, barcode scanners, and label printers. Its software offerings include You-R Smart Fashion for textile supply chains, You-R® DOCUTRACER for data management in legal and healthcare sectors, You-R® PHARMA for pharmaceutical packaging, You-R® RETAIL for inventory management, You-R® SECURE for brand protection, and You-R® VIRTUAL TUNNEL for unit allocation in packaging. Alongside its products, RF-iT Solutions provides consulting services, feasibility studies, and testing to various industries, including fashion, automotive, pharmaceuticals, retail, and healthcare.
Deinove
Funding Round in 2006
Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.
TheraDiag
Series C in 2005
TheraDiag is a France-based company specializing in the development, manufacturing, and marketing of in-vitro diagnostic products. Founded in 1986 and headquartered in Marne La Vallée, the company offers a range of diagnostic tools, including reagents for autoimmune and infectious diseases, as well as fertility tests. Notable products include IMMUNO-TROL, a quality control tool; various instruments for disease testing; and the SQA-V semen analyzer. TheraDiag also provides advanced instrumentation such as the Theralis platform, which integrates immunofluorescence and ELISA technologies, and the FIDIS platform for laboratory analysis. Additionally, the company offers therapeutic drug monitoring services for chronic inflammatory diseases and LISA tracker, a tool designed for monitoring biotherapies.
AS Group
Funding Round in 2005
AS Group is a Parisian company and a spin-off of Deloitte, was a corporate performance software vendor.
Equitime
Funding Round in 2004
EquiTime is a provider of workforce management solutions designed to assist organizations in effectively managing employee schedules while accommodating the unique requirements of various professions. The company innovates traditional time and activity management by incorporating forecasting capabilities alongside actual work performance, thereby enhancing productivity and fostering better relationships between employees and customers. EquiTime's core product, AgileTime, is complemented by a range of services including training, integration with human resource information systems (HRIS), tailored developments, and functional support, ensuring clients can fully leverage the benefits of their workforce management systems.
TheraDiag
Series B in 2003
TheraDiag is a France-based company specializing in the development, manufacturing, and marketing of in-vitro diagnostic products. Founded in 1986 and headquartered in Marne La Vallée, the company offers a range of diagnostic tools, including reagents for autoimmune and infectious diseases, as well as fertility tests. Notable products include IMMUNO-TROL, a quality control tool; various instruments for disease testing; and the SQA-V semen analyzer. TheraDiag also provides advanced instrumentation such as the Theralis platform, which integrates immunofluorescence and ELISA technologies, and the FIDIS platform for laboratory analysis. Additionally, the company offers therapeutic drug monitoring services for chronic inflammatory diseases and LISA tracker, a tool designed for monitoring biotherapies.